Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research

Franziska Hufsky, Kevin Lamkiewicz, Alexandre Almeida, Abdel Aouacheria, Cecilia N. Arighi, Alex Bateman, Jan Baumbach, Niko Beerenwinkel, Christian Brandt, Marco Cacciabue, Sara Chuguransky, Oliver Drechsel, Robert D. Finn, Adrian Fritz, Stephan Fuchs, Georges Hattab, Anne-Christin Hauschild, Dominik Heider, Marie Hoffmann, Martin Hölzer, Stefan Hoops, Lars Kaderali, Ioanna Kalvari, Max von Kleist, Renó Kmiecinski, Denise Kühnert, Gorka Lasso, Pieter Libin, Markus List, Hannah F. Löchel, Maria Jesus Martin, Roman Martin, Julian O. Matschinske, Alice C. McHardy, Pedro Mendes, Jaina Mistry, Vincent Navratil, Eric P. Nawrocki, Áine Niamh O'toole, Nancy Ontiveros-Palacios, Anton I. Petrov, Guillermo Rangel-Pineros, Nicole Redaschi, Susanne Reimering, Knut Reinert, Alejandro Reyes, Lorna J. Richardson, David L. Robertson, Sepideh Sadegh, Joshua B. Singer, Kristof Theys, Chris Upton, Marius Welzel, Lowri Williams, Manja Marz

TL;DR

The COVID-19 pandemic has spurred an unprecedented surge in SARS-CoV-2 research, necessitating rapid development and deployment of computational tools. This review provides a comprehensive overview of existing and newly developed bioinformatics workflows and tools that accelerate research across detection, sequencing analysis, epidemiological tracking, evolutionary studies, and drug discovery for SARS-CoV-2.

What Problem Does This Paper Address?

The COVID-19 pandemic presented an urgent global health crisis, demanding swift scientific understanding and intervention. The sheer volume and complexity of data generated by SARS-CoV-2 research—from genomic sequencing to epidemiological tracking—overwhelmed traditional research methods. This paper addresses the critical need for accessible, efficient, and robust computational tools to analyze this data, enabling faster detection, better understanding of the virus's evolution and spread, and ultimately, the development of effective treatments and containment strategies.

Methods

This paper is a review, not a primary research article, so it doesn't introduce novel methods. Instead, it surveys and categorizes existing and recently developed bioinformatics tools. These tools employ a range of computational strategies, including:

  • Primer Design: Tools like PriSeT identify specific DNA sequences for RT-PCR tests, crucial for accurate and rapid detection of SARS-CoV-2.
  • Genome Reconstruction & Analysis: Pipelines such as CoVPipe, V-Pipe, and poreCov utilize next-generation sequencing (NGS) data (including nanopore sequencing) for rapid genome assembly, variant calling, and intra-host diversity analysis.
  • Annotation & Validation: VADR and VIRULIGN provide tools for annotating viral genomes and performing codon-correct multiple sequence alignments, essential for understanding viral structure and evolution.
  • Epidemiological Tracking & Phylodynamics: Tools like Pangolin, BEAST 2, and Covidex leverage phylogenetic analysis, Bayesian inference, and machine learning to track viral lineages, reconstruct spread patterns, and model epidemic dynamics.
  • Drug Discovery & Repurposing: Databases and platforms like VirHostNet, CORDITE, CoVex, and P-HIPSTer integrate virus-host interactions, drug-target data, and protein-protein interaction networks to identify potential drug targets and facilitate drug repurposing.

Datasets

The paper discusses the use of various datasets, primarily focusing on publicly available genomic and epidemiological data related to SARS-CoV-2. Key data sources mentioned include:

  • GenBank: A public repository for nucleotide sequences, including SARS-CoV-2 genomes.
  • GISAID (Global Initiative on Sharing All Influenza Data): A crucial platform for rapid sharing of SARS-CoV-2 genomic sequences and associated metadata.
  • UniProt: A comprehensive database of protein sequences and functional information, with a dedicated COVID-19 portal.
  • Pfam: A database of protein families, used for annotating SARS-CoV-2 proteins.
  • Rfam: A database of RNA families, used for annotating structured RNAs in coronaviruses.
  • Clinical Trial Databases (e.g., NIH): Used for tracking potential drug candidates.

The paper emphasizes the importance of open data sharing, particularly through GISAID and GenBank, for accelerating research.

Key Insights and Ideas

  • The Power of Open Science: The rapid development and sharing of bioinformatics tools and data (especially genomic sequences via GISAID) have been instrumental in accelerating SARS-CoV-2 research.
  • Tool Specialization: No single tool can address all research needs. The review highlights a diverse ecosystem of specialized tools for different stages of research, from initial detection to drug development.
  • Repurposing Existing Tools: Many effective strategies involve adapting existing bioinformatics tools and databases developed for other viruses or biological systems to the specific challenges posed by SARS-CoV-2.
  • The Importance of Phylodynamics: Understanding the evolutionary dynamics and geographical spread of SARS-CoV-2 through phylodynamic modeling is critical for predicting pandemic trajectories and informing public health interventions.
  • Drug Repurposing as a Strategy: Given the urgency, repurposing existing drugs and identifying virus-host interactions are key strategies for rapid therapeutic development.

Key Results

This review doesn't present quantitative results in the traditional sense, as it's a survey of tools. However, it highlights the capabilities of various tools:

  • Rapid Detection: Tools like PriSeT enable the design of specific primers for fast and accurate RT-PCR detection.
  • Efficient Sequencing Analysis: Workflows like poreCov can deliver a consensus viral genome in approximately 7 hours from nanopore sequencing data.
  • Comprehensive Annotation: VADR can annotate viral sequences and identify over 40 types of potential errors, aiding in data quality control.
  • Lineage Assignment: Pangolin can assign global lineages to SARS-CoV-2 genomes, crucial for tracking the pandemic's evolution.
  • Drug Target Identification: VirHostNet and CoVex can identify potential drug targets and repurposable drug candidates by analyzing complex interaction networks.

Limitations and Future Work

  • Tool Maintenance and Sustainability: The authors note that the lifecycle of research software is often short due to limited funding for continuous maintenance, posing a challenge for long-term usability.
  • Need for Standardization and Integration: While many tools exist, there's a need for better integration and standardization to create more seamless processing pipelines.
  • Ongoing Development: The paper acknowledges that the rapid pace of research means new tools will continue to emerge, and the review provides a snapshot in time.
  • Reproducibility: The authors emphasize the importance of reproducible workflows, often achieved through containerization (Docker, Singularity) and workflow management systems (Snakemake, Nextflow), suggesting this will be a focus for future tool development.
  • Data Accessibility: While open access is encouraged, the paper notes that legal restrictions (e.g., on GISAID data) can sometimes limit the open-source release of certain packages.

Summary updated

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel virus of the family Coronaviridae. The virus causes the infectious disease COVID-19. The biology of coronaviruses has been studied for many years. However, bioinformatics tools designed explicitly for SARS-CoV-2 have only recently been developed as a rapid reaction to the need for fast detection, understanding, and treatment of COVID-19. To control the ongoing COVID-19 pandemic, it is of utmost importance to get insight into the evolution and pathogenesis of the virus. In this review, we cover bioinformatics workflows and tools for the routine detection of SARS-CoV-2 infection, the reliable analysis of sequencing data, the tracking of the COVID-19 pandemic and evaluation of containment measures, the study of coronavirus evolution, the discovery of potential drug targets and development of therapeutic strategies. For each tool, we briefly describe its use case and how it advances research specifically for SARS-CoV-2. All tools are freely available online, either through web applications or public code repositories.
BibTeX
@article{hufsky2021computational,
  author = {Franziska Hufsky and Kevin Lamkiewicz and Alexandre Almeida and Abdel Aouacheria and Cecilia N. Arighi and Alex Bateman and Jan Baumbach and Niko Beerenwinkel and Christian Brandt and Marco Cacciabue and Sara Chuguransky and Oliver Drechsel and Robert D. Finn and Adrian Fritz and Stephan Fuchs and Georges Hattab and Anne-Christin Hauschild and Dominik Heider and Marie Hoffmann and Martin Hölzer and Stefan Hoops and Lars Kaderali and Ioanna Kalvari and Max von Kleist and Renó Kmiecinski and Denise Kühnert and Gorka Lasso and Pieter Libin and Markus List and Hannah F. Löchel and Maria Jesus Martin and Roman Martin and Julian O. Matschinske and Alice C. McHardy and Pedro Mendes and Jaina Mistry and Vincent Navratil and Eric P. Nawrocki and Áine Niamh O'toole and Nancy Ontiveros-Palacios and Anton I. Petrov and Guillermo Rangel-Pineros and Nicole Redaschi and Susanne Reimering and Knut Reinert and Alejandro Reyes and Lorna J. Richardson and David L. Robertson and Sepideh Sadegh and Joshua B. Singer and Kristof Theys and Chris Upton and Marius Welzel and Lowri Williams and Manja Marz},
  title = {{Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research}},
  journal = {Briefings in Bioinformatics},
  year = {2021},
  doi = {10.1093/bib/bbaa232},
}
Figure